Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.

British journal of clinical pharmacology - 1 May 2018

Zhao Wei, Leroux Stéphanie, Biran Valérie, Jacqz-Aigrain Evelyne

Abstract excerpt

AIMS: Although substantial progress has been made in understanding of ontogeny of drug metabolism, there is still a gap of knowledge in developmental pharmacogenetics in neonates. We hypothesized that both age and pharmacogenetics might explain the developmental pattern of CYP2C19. We conducted a population pharmacokinetic-pharmacogenetic study to quantify the developmental pharmacogenetics of CYP2C19 in neonates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Homozygote

Share to Infant, Newborn

Share to Models, Biological

Share to Omeprazole

Share to Proton Pump Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 29377228
DOI: 10.1111/bcp.13526
PMCID: PMC5903239

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.PMID 29377228Read ↗

Interpreting Pharmacogenetic Data in the Developing Neonate: The Challenge of Hitting a Moving TargetSemantic proximity Read ↗

Challenges for drug studies in children: CYP3A phenotyping as example.Semantic proximity Read ↗

Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children.Semantic proximity Read ↗

Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Semantic proximity Read ↗

Omeprazole disposition in children following single-dose administration.Semantic proximity Read ↗

Meta‐analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modelingSemantic proximity Read ↗

Ontogeny and drug metabolism in newbornsSemantic proximity Read ↗

Metabolism of omeprazole after two oral doses in children 1 to 9 months old.Semantic proximity Read ↗

Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolismSemantic proximity Read ↗

Ontogeny of Phase I Metabolism of DrugsSemantic proximity Read ↗

Age-Dependent Abundance of CYP450 Enzymes Involved in Metronidazole Metabolism: Application to Pediatric PBPK Modeling.Semantic proximity Read ↗

Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.